Steroids for inflammation-related heart failure shock
Part of Heart & circulation clinical trials.
This trial tests if a steroid medicine can help people with cardiogenic shock from heart failure who have high inflammation levels. It aims to see if reducing inflammation improves recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You are in the intensive care unit with cardiogenic shock (very low blood pressure or needing medications to keep it up).
- Your shock is caused by worsening chronic heart failure, not a heart attack.
- You have a history of heart failure with reduced pumping function (LVEF under 40%).
- You have high inflammation levels, shown by a blood test (hsCRP 20 mg/L or more).
- You have been in the hospital less than 48 hours.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how well people with cardiogenic shock (a life-threatening drop in blood flow after a heart attack or heart failure worsening) do when treated with modern support devices and medicines.
This study looks at whether adding two simple blood test markers to a standard heart failure score can better predict recovery in people with cardiogenic shock, a condition where the heart cannot pump enough blood. The goal is to help doctors tailor treatment for each patient.
This trial is testing different approaches (medications and mechanical support) to help people with acute heart failure and cardiogenic shock (a sudden drop in the heart's pumping ability). It looks at how well these treatments work in a network of hospitals to improve outcomes.
This trial tests a medication called istaroxime to help patients with acute heart failure and very low blood pressure (cardiogenic shock). The goal is to see if it can improve heart function and help patients recover faster.
This trial studies how to identify different types of “cardiogenic shock,” a serious drop in heart blood flow. It aims to use detailed patient information to guide care and possibly lower the chance of dangerous outcomes.
This study compares two treatment strategies for people with unexplained heart failure and irregular heartbeats caused by inflammation: one group gets standard heart medications plus an immune-suppressing steroid (prednisone), and the other gets standard medications alone. Doctors want to see whether adding steroids helps improve heart function and control dangerous heart rhythms.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.